repaglinide

⇄

cytochrome P450 family 2 subfamily C member 8 ; Homo sapiens







39 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 32970826 Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration. 2021 May 1
2 32206324 Risk of hypoglycemia associated with repaglinide combined with clopidogrel, a retrospective cohort study. 2020 5
3 33088647 Severe hypoglycemia caused by a small dose of repaglinide and concurrent use of nilotinib and febuxostat in a patient with type 2 diabetes. 2020 Oct 1
4 29901213 PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling. 2019 Feb 2
5 30636597 Effects of CYP2C8 and SLCO1B1 Genetic Polymorphisms on Repaglinide Pharmacokinetics: A Systematic Review and Meta-Analysis. 2019 2
6 31129789 Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole. 2019 Dec 1
7 29381228 Implications of intercorrelation between hepatic CYP3A4-CYP2C8 enzymes for the evaluation of drug-drug interactions: a case study with repaglinide. 2018 May 1
8 27599706 Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. 2017 Apr 1
9 28238899 Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions. 2017 Sep 4
10 28479356 Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data. 2017 Sep 2
11 28653847 Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8). 2017 Nov 9 1
12 26721703 Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. 2016 Jan 1
13 27259818 CYP2C8-mediated interaction between repaglinide and steviol acyl glucuronide: In vitro investigations using rat and human matrices and in vivo pharmacokinetic evaluation in rats. 2016 Aug 2
14 27457785 Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. 2016 Oct 1
15 25595597 A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. 2015 Apr 1
16 26296069 Physiologically based pharmacokinetics model predicts the lack of inhibition by repaglinide on the metabolism of pioglitazone. 2015 Dec 1
17 24623479 Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk. 2014 Sep 1
18 24971633 Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. 2014 Oct 1
19 23393219 Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. 2013 May 1
20 23536207 Influence of CYP2C8 polymorphisms on the hydroxylation metabolism of paclitaxel, repaglinide and ibuprofen enantiomers in vitro. 2013 Jul 10
21 22451699 A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. 2012 Jul 3
22 23153186 CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. 2012 Dec 1
23 21270106 Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. 2011 May 4
24 21778352 Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. 2011 Oct 1
25 20197475 Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. 2010 Apr 2
26 20523106 CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics. 2010 1
27 19761371 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. 2009 Sep 2
28 17923851 Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. 2008 Aug 2
29 17253883 Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. 2007 2
30 16299161 Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. 2006 Jan 1
31 16447051 Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. 2006 Mar 1
32 16513447 Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. 2006 Mar 1
33 15601807 Examination of 209 drugs for inhibition of cytochrome P450 2C8. 2005 Jan 1
34 16176562 Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. 2005 Oct 5
35 16198658 Cyclosporine markedly raises the plasma concentrations of repaglinide. 2005 Oct 1
36 16372821 Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. 2005 2
37 15025742 The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. 2004 Apr 3
38 12919179 CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. 2003 Sep 3
39 14534525 Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. 2003 Oct 5